Drug Regulator’s Nod Sought For Phase-3 Study Of Intranasal Covid Vaccine In 5-18 Age Group

On September 6, the Drugs Controller General of India (DCGI) had approved its intranasal Covid vaccine iNCOVACC for restricted emergency use in those aged above 18 years.  ‘Now the Hyderabad based firm has submitted an application seeking permission to conduct phase-3, multicenter study to evaluate the safety, reactogenicity and immunogenicity of iNCOVACC (BBV154) in those aged 18 to 5 years,’ an official source told PTI.